vs
Side-by-side financial comparison of Royalty Pharma plc (RPRX) and SM Energy Co (SM). Click either name above to swap in a different company.
SM Energy Co is the larger business by last-quarter revenue ($704.9M vs $622.0M, roughly 1.1× Royalty Pharma plc). On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -17.3%). Over the past eight quarters, SM Energy Co's revenue compounded faster (12.2% CAGR vs 4.6%).
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
SM Energy Company is a company engaged in hydrocarbon exploration. It is organized in Delaware and headquartered in Denver, Colorado.
RPRX vs SM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $622.0M | $704.9M |
| Net Profit | $214.2M | — |
| Gross Margin | — | — |
| Operating Margin | 62.4% | 25.9% |
| Net Margin | 34.4% | — |
| Revenue YoY | 4.8% | -17.3% |
| Net Profit YoY | 2.9% | — |
| EPS (diluted) | $0.49 | $0.94 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $622.0M | $704.9M | ||
| Q3 25 | $609.3M | $811.6M | ||
| Q2 25 | $578.7M | $792.9M | ||
| Q1 25 | $568.2M | $844.5M | ||
| Q4 24 | $593.6M | $852.0M | ||
| Q3 24 | $564.7M | $643.6M | ||
| Q2 24 | $537.3M | $634.6M | ||
| Q1 24 | $568.0M | $559.9M |
| Q4 25 | $214.2M | — | ||
| Q3 25 | $288.2M | $155.1M | ||
| Q2 25 | $30.2M | $201.7M | ||
| Q1 25 | $238.3M | $182.3M | ||
| Q4 24 | $208.2M | — | ||
| Q3 24 | $544.0M | $240.5M | ||
| Q2 24 | $102.0M | $210.3M | ||
| Q1 24 | $4.8M | $131.2M |
| Q4 25 | 62.4% | 25.9% | ||
| Q3 25 | 70.1% | 30.4% | ||
| Q2 25 | 36.3% | 37.2% | ||
| Q1 25 | 94.0% | 32.7% | ||
| Q4 24 | 60.9% | 33.7% | ||
| Q3 24 | — | 51.4% | ||
| Q2 24 | 50.2% | 44.0% | ||
| Q1 24 | -13.0% | 31.9% |
| Q4 25 | 34.4% | — | ||
| Q3 25 | 47.3% | 19.1% | ||
| Q2 25 | 5.2% | 25.4% | ||
| Q1 25 | 41.9% | 21.6% | ||
| Q4 24 | 35.1% | — | ||
| Q3 24 | 96.3% | 37.4% | ||
| Q2 24 | 19.0% | 33.1% | ||
| Q1 24 | 0.8% | 23.4% |
| Q4 25 | $0.49 | $0.94 | ||
| Q3 25 | $0.67 | $1.35 | ||
| Q2 25 | $0.07 | $1.76 | ||
| Q1 25 | $0.55 | $1.59 | ||
| Q4 24 | $0.46 | $1.63 | ||
| Q3 24 | $1.21 | $2.09 | ||
| Q2 24 | $0.23 | $1.82 | ||
| Q1 24 | $0.01 | $1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $618.7M | $368.0M |
| Total DebtLower is stronger | $9.0B | — |
| Stockholders' EquityBook value | $9.7B | $4.8B |
| Total Assets | $19.6B | $9.3B |
| Debt / EquityLower = less leverage | 0.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $618.7M | $368.0M | ||
| Q3 25 | $938.9M | $162.3M | ||
| Q2 25 | $631.9M | $101.9M | ||
| Q1 25 | $1.1B | $54.0K | ||
| Q4 24 | $929.0M | — | ||
| Q3 24 | $950.1M | $1.7B | ||
| Q2 24 | $1.8B | $487.9M | ||
| Q1 24 | $843.0M | $506.3M |
| Q4 25 | $9.0B | — | ||
| Q3 25 | $8.9B | — | ||
| Q2 25 | $8.0B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.6B | — | ||
| Q3 24 | $7.6B | — | ||
| Q2 24 | $7.6B | — | ||
| Q1 24 | $6.1B | — |
| Q4 25 | $9.7B | $4.8B | ||
| Q3 25 | $9.6B | $4.7B | ||
| Q2 25 | $9.5B | $4.6B | ||
| Q1 25 | $9.8B | $4.4B | ||
| Q4 24 | $10.3B | $4.2B | ||
| Q3 24 | $10.3B | $4.1B | ||
| Q2 24 | $9.8B | $3.8B | ||
| Q1 24 | $9.9B | $3.7B |
| Q4 25 | $19.6B | $9.3B | ||
| Q3 25 | $19.3B | $9.1B | ||
| Q2 25 | $18.3B | $9.0B | ||
| Q1 25 | $17.6B | $8.8B | ||
| Q4 24 | $18.2B | $8.6B | ||
| Q3 24 | $18.0B | $8.0B | ||
| Q2 24 | $17.7B | $6.7B | ||
| Q1 24 | $16.1B | $6.4B |
| Q4 25 | 0.92× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 0.84× | — | ||
| Q1 25 | 0.78× | — | ||
| Q4 24 | 0.74× | — | ||
| Q3 24 | 0.74× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.62× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $827.1M | $451.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.86× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $827.1M | $451.9M | ||
| Q3 25 | $702.6M | $505.0M | ||
| Q2 25 | $364.0M | $571.1M | ||
| Q1 25 | $596.1M | $483.0M | ||
| Q4 24 | $742.5M | $578.4M | ||
| Q3 24 | $703.6M | $452.3M | ||
| Q2 24 | $658.2M | $476.4M | ||
| Q1 24 | $664.6M | $276.0M |
| Q4 25 | 3.86× | — | ||
| Q3 25 | 2.44× | 3.26× | ||
| Q2 25 | 12.06× | 2.83× | ||
| Q1 25 | 2.50× | 2.65× | ||
| Q4 24 | 3.57× | — | ||
| Q3 24 | 1.29× | 1.88× | ||
| Q2 24 | 6.45× | 2.27× | ||
| Q1 24 | 139.10× | 2.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
SM
Segment breakdown not available.
